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HLA-C mismatches are clearly associated to alloreactivity after hematopoietic stem-cell
transplantation; in a number of large cohorts, HLA-C mismatches are correlated to an
increased risk of acute graft-versus-host disease (GVHD) or even impaired survival. While
for HLA-A and -B, both antigenic as well as allelic mismatches are associated with an
increased risk of acute GVHD, such an increased risk is only observed for antigenic HLA-C
mismatches and not for allelic mismatches. These observations raise the question what
sets HLA-C apart from HLA-A and -B. The difference may well be related to the reduced
levels of cell-surface expression of HLA-C as compared to HLA-A and -B, possibly due
to, among other factors, a limited peptide-binding capacity. This limited peptide-binding
capacity may retain HLA-C in the ER and enhance degradation of the HLA-C protein. Once
degraded, HLA-C-derived peptides can be presented to the immune system via other HLA
alleles and are thus available for indirect recognition. Indeed, such HLA-C-derived pep-
tides have previously been eluted from other HLA alleles. We have recently developed an
approach to predict indirect recognition of HLA molecules, by establishing the numbers of
predicted indirectly recognizable HLA epitopes (PIRCHES). The number of PIRCHES pre-
sented on HLA class I and II (PIRCHE-I and -II, respectively), are highly correlated to clinical
measures of alloreactivity, such as acute GVHD. In the present “Hypothesis &Theory,” we
reviewed the current knowledge on HLA-C mismatches and alloreactivity. Moreover, we
speculate about the role of direct and indirect recognition of HLA-C and the consequences
for donor selection in HLA-C mismatched stem-cell transplantation.
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INTRODUCTION
HLA-C is a classical HLA class-I protein, thus expressed on nucle-
ated cells and is able to present peptides to T-cells. Like the
other classical HLA class-I proteins (HLA-A and -B), HLA-C con-
sists of a polymorphic heavy chain and the non-polymorphic
β2-microglobulin. The coding region for the heavy chain is
located on chromosome six, in close vicinity of the HLA-B locus.
HLA-C and -B alleles are therefore often inherited in non-random
combinations, the so-called linkage disequilibrium.
Under normal conditions, HLA-C is expressed at low levels on
the cell surface. This low expression level is likely the result of
multiple factors: the HLA-C heavy chain messenger RNA is unsta-
ble (1); the HLA-C heavy chain does not associate efficiently with
the β2-microglobulin (2–4); HLA-C presents a rather restricted
repertoire of peptides due to a very restricted α1 domain (5, 6).
Due to the restricted peptide repertoire and the inefficient associ-
ation with β2-microglobulin, HLA-C is often retained within the
endoplasmic reticulum (ER) and degraded (4, 6, 7). Next to pre-
senting peptides, HLA-C also serves as a ligand for natural killer
(NK) cell receptors: killer immunoglobulin-like receptors (KIR).
HLA-C binding to KIRs can act as a negative or positive signal for
the NK cells. It is often proposed that the negative signal is the
main function of HLA-C and that therefore HLA-C cell-surface
expression levels are low (7) [for a comprehensive review regarding
the function of HLA-C in relation to KIR, see (8)].
Despite the low expression level of HLA-C, HLA-C mismatches
are clearly associated to alloreactivity after hematopoietic stem-cell
transplantation (HSCT): in a number of large cohorts HLA-C mis-
matches are correlated to an increased risk of acute graft-versus-
host disease (GVHD) or even impaired survival (Figures 1A,B)
(9–13). Interestingly, for other HLA class-I mismatches (HLA-
A and -B) both low-resolution level (antigenic) as well as
high-resolution level (allelic) mismatches are associated with an
increased risk of acute GVHD; whereas for HLA-C mismatches
this increased risk is only observed for HLA-C antigenic mis-
matches (9, 12). The effect of HLA-C mismatches on alloreactivity
may be explained by NK-cell recognition, however, the exact role
of missing KIR ligands in HLA-C mismatched HSCT remains
to be elucidated (14). On the other hand, development of acute
GVHD clearly involves antigen recognition by T-cells [As reviewed
in (15)]. The aim of this “Hypothesis & Theory” paper is to
provide a potential explanation for the high immunogenicity of
HLA-C antigenic mismatches, despite the low cell-surface expres-
sion levels. This potential explanation is based on how T-cell recog-
nition might be involved in the alloreactivity related to HLA-C
mismatches.
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T-CELL ALLOREACTIVITY
HLA mismatches can lead to T-cell induced alloreactivity via two
routes: direct or indirect recognition. Direct recognition is the
process where the donor T cell recognizes the intact mismatched
HLA molecule on the cell surface of recipient’s cells. Direct recog-
nition is unlikely in the case of HLA-C mismatches because of
the low cell-surface expression levels. Indirect recognition occurs
when the mismatched HLA protein is processed within the cell
and is presented as peptides by HLA molecules. At least 59 pep-
tides derived from HLA-C have been eluted from HLA (16). When
the mismatched HLA-C-derived peptides differ from self peptides,
they can be recognized by T-cells.
FIGURE 1 | (A) Forest plot for relative risk of acute GVHD III-IV of HLA-C
mismatches compared to HLA-matched transplants. (B) Forest plot for
relative risk of mortality of HLA-C mismatches compared to HLA-matched
transplants. #: (10) 33 cases of an HLA-C mismatch (either allelic or
antigenic, also in combination with other mismatched loci) were compared
to 78 10/10 matches. $: Authors indicated hazard ratios. ∧: (11) 749 HLA-C
mismatches (either allelic or antigenic) were compared to 108 8/8 matches.
+: (9) 189 HLA-C antigenic mismatches and 61 HLA-C allelic mismatches
were compared to 1243 8/8 matches. ~: (12) 382 HLA-C antigenic
mismatches and 96 HLA-C allelic mismatches were compared to 1840 8/8
matches. 0: (13) 300 HLA-C antigenic and 57 HLA-C allelic mismatches
were compared to 1511 10/10 matches. 10/10 match: donor and recipient
matched on high-resolution level for HLA-A, -B, -C, -DRB1, and -DQB1. 8/8
match: donor and recipient matched on high-resolution level for HLA-A, -B,
-C, and -DRB1. MM: mismatch. RR: relative risk, relative to either 8/8 or
10/10 matches, as indicated.
Our group has recently developed an approach to predict
indirect recognition of mismatched HLA, by establishing the num-
bers of predicted indirectly recognizable HLA epitopes (PIRCHES)
(17). The number of PIRCHES presented on HLA class I and II,
PIRCHE-I and -II respectively, are highly correlated to clinical
measures of alloreactivity, such as acute GVHD and transplant-
related mortality (Thus et al., manuscripts in preparation).
HLA-C-DERIVED PIRCHES
Thus, we hypothesize that the thusfar unexplained substantial
alloreactivity of HLA-C mismatches evolves due to indirect recog-
nition of HLA-C. Indirect recognition may furthermore explain
the observation that HLA-C antigenic mismatches specifically lead
to alloreactivity, as antigenic mismatches likely lead to a higher
number of indirectly recognizable epitopes compared to allelic
mismatches. To support these hypotheses, we analyzed our local
cohort of patients transplanted with an unrelated single HLA-
mismatched donor (a 9/10) after non-myeloablative conditioning.
All patients and donors were typed for HLA-A, -B, -C, -DRB1, and
-DQB1, at ultra-high (4-digit) resolution level, resolving all ambi-
guities. For retrospective high-resolution HLA-C typing of one
HSCT pair, no remaining DNA was available. For this single situa-
tion, the high-resolution HLA-typing of this donor–recipient pair
was deduced based upon the low-resolution HLA-C typing using
the HLA-B/-C association probability (18). The majority of the
48 patients included in these analyses, were transplanted with a
mismatch for HLA-C (N = 20, 42%, Table 1).
PIRCHES were determined in the previously described manner
(17) with some adaptations; differences in the current study are
the incorporation of NetMHCIIPan 2.0, and NetChop for predict-
ing processing of peptides with a processing probability of >0.5
and NetMHCPan 2.4 to select potential binders with an IC50 value
<500 nM for predicting PIRCHE-I (19–22).
We first analyzed the numbers of PIRCHE-I and -II separate
per mismatched HLA locus (Figures 2A,B). HLA-C mismatches
yielded the highest numbers of PIRCHE-I (Figure 2A), although
the numbers of PIRCHE-I derived from HLA-C were not sig-
nificantly different when compared to those derived from the
other loci, likely due to the low patient numbers. The num-
ber of PIRCHE-II derived from HLA-C were significantly higher
than those derived from HLA-B and HLA-DQB1 (Figure 2B,
Table 1 |The number and percentage of patients, per mismatched
locus.
Mismatch locus N (%)
HLA-A 10 (21)
HLA-B 6 (13)
HLA-C 20 (42)
HLA-DRB1 2 (4)
HLA-DQB1 10 (21)
We investigated our complete local cohort of patients transplanted with a single
HLA-mismatched unrelated donor (a 9/10 match) after non-myeloablative condi-
tioning, for various underlying diseases.The majority (42%) was transplanted with
an HLA-C mismatch.
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FIGURE 2 | (A)The number of PIRCHE-I displayed by the mismatched locus
they are derived from. (B)The number of PIRCHE-II displayed by the
mismatched locus they are derived from. (C)The number of PIRCHE-I derived
from an HLA-C allelic versus antigenic mismatch. (D)The number of
PIRCHE-II derived from an HLA-C allelic versus antigenic mismatch. Horizontal
lines indicate the median value and the differences between groups were
tested with Mann–Whitney U tests. Patients with an HLA-C mismatch had a
significantly higher number of PIRCHE-II compared to patients with an HLA-B
or -DQB1 mismatch. Patients with HLA-C antigenic mismatches, had higher
number of PIRCHE-I and -II compared to allelic mismatches.
p= 0.04 and p< 0.01, respectively). The majority of the
HLA-C mismatches were antigenic mismatches (N = 18, 90%).
The abundance of antigenic HLA-C mismatches may explain
the high PIRCHE numbers, as the antigenic HLA-C mismatches
led to significantly higher numbers of PIRCHES than the allelic
mismatches (p= 0.03 and p= 0.02 for PIRCHE-I and -II, respec-
tively). Allelic HLA-C mismatches always resulted in 0 PIRCHE-I,
whereas the number of PIRCHE-II did not exceed 1. Antigenic
HLA-C mismatches led to a median of 6 PIRCHE-I (range 0–11),
and a median of 18 PIRCHE-II (range 1–32) (Figures 2C,D).
To investigate whether indirect recognition of HLA-C pre-
dicts alloreactivity, we selected the HLA-C mismatched trans-
plantations only. We subsequently analyzed whether the risk of
alloreactivity is related to the number of PIRCHES instead of the
allelic versus antigenic definition. To this end, we redefined the
HLA-C mismatches into low or higher number of PIRCHES. We
defined 0 PIRCHE-I as low PIRCHE-I, as this was the number of
PIRCHES derived from the allelic mismatches, and we defined≤1
PIRCHE-II as low PIRCHE-II, as 1 was the maximum number
of PIRCHE-II derived from the allelic mismatches. Interestingly,
we have previously shown that these cut-offs were also the cut
off values of the lowest tertiles of HLA-DPB1 derived PIRCHES
(manuscript in preparation).
For all transplant recipients, the numbers of PIRCHES were
correlated to acute GVHD development. We observe a trend
for patients in the higher PIRCHE-I or -II group having an
increased probability of acute GVHD compared to the low
PIRCHES (Figures 3A,B). Patients presenting low HLA-C-derived
PIRCHE-I or -II (N = 3) did not develop acute GVHD. This differ-
ence is, although striking, not significant, likely due to low patient
and event numbers (six events). The number of PIRCHES is not
associated to the severity of acute GVHD in this cohort, although
such an association requires a larger study population; we observed
only three cases of clinically severe acute GVHD (grade III-IV).
POTENTIAL IMPLICATIONS FOR DONOR SELECTION
For HSCT donor-selection procedures, potential donors are at
first mainly typed on a low to intermediate resolution level for
HLA-A, -B, and -DRB1. Based on donor–recipient matching for
these loci, a limited number of donors are selected for further
high-resolution typing, which includes typing of the other loci.
For patients with rare HLA-B/-C associations, it will be very chal-
lenging to find a donor matched for both HLA-B and -C, due to the
strong linkage disequilibrium between HLA-B and -C. As HLA-B
matching is considered earlier in the donor-selection procedure
than HLA-C, patients with rare HLA-B/-C associations are more
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FIGURE 3 | (A) Probability of acute GVHD by HLA-C-derived PIRCHE-I low
or PIRCHE-I higher. (B) Probability of acute GVHD by HLA-C-derived
PIRCHE-II low or PIRCHE-II higher. Kaplan–Meier curves were constructed
to analyze the probability of developing acute GVHD II-IV for patients in the
low (in gray) and higher (in black) PIRCHE groups. Patients with low
PIRCHE-I did not develop acute GVHD. Patients with low PIRCHE-II did not
develop acute GVHD. Probabilities of acute GVHD II-IV were not
significantly different amongst the low or higher PIRCHE groups as tested
with log-rank tests. GVHD: graft-versus-host disease; HSCT: hematopoietic
stem-cell transplantation.
frequently transplanted with an HLA-C mismatch. These HLA-C
mismatches are often antigenic mismatches, as can be expected
from the observed HLA-B/-C associations (18). Our data indi-
cate that these antigenic HLA-C mismatches very frequently lead
to high numbers of PIRCHES, due to the low level of homology
between the two mismatched alleles. We propose that a mismatch
for HLA-B may be considered in these cases, as in some situations
the HLA-B mismatches can lead to lower numbers of PIRCHES
than HLA-C mismatches.
To support the above-mentioned option, we performed a theo-
retical analysis. To this end, we analyzed the possibility to identify
an alternative 9/10 mismatched donor for those HLA-C mis-
matched cases that had an increased probability of acute GVHD
(i.e., PIRCHE-I> 0 and PIRCHE-II> 1, N = 17), using haplotype
frequency tables (18). For these patients, we aimed at a theoret-
ical HLA-B mismatch instead of an HLA-C mismatch. For 13
(76%) patients, we could identify a potential HLA-B mismatched
donor (Table 2). In 7 (54%) of these cases, the HLA-B mismatch
led to a lower number of PIRCHE-I than the selected HLA-C
mismatched donor, and in 9 (69%) of the cases the HLA-B mis-
match yielded a lower number of PIRCHE-II than the HLA-C
mismatch (Figures 4A,B). The numbers of PIRCHE-II related
to an HLA-B mismatch instead of an HLA-C mismatch, are sig-
nificantly reduced for the HLA-B mismatched cases (p= 0.03).
Thus, HLA-B mismatches can lead to a lower probability of indi-
rect recognition than HLA-C mismatches. We hypothesize that
the effect of HLA mismatches does not depend on a locus-specific
effect, but is rather related to the resulting PIRCHES.
DISCUSSION
HLA-C mismatches lead to substantial alloreactivity, despite the
low cell-surface expression levels of HLA-C. Particularly, antigenic
HLA-C mismatches lead to high risks of complications (Figure 1).
In our local cohort of patients transplanted with a single HLA
mismatch, we show that HLA-C mismatches lead to higher num-
bers of indirectly recognizable epitopes (PIRCHES) than when
mismatches are located on other loci (Figure 2). Furthermore,
patients presenting HLA-C-derived PIRCHE-I or more than one
HLA-C-derived PIRCHE-II are at a higher risk of developing acute
GVHD. Indirect recognition of HLA-C mismatches may therefore
provide an explanation for the alloreactive complications observed
after HLA-C mismatched transplants.
In theory, HLA-C allelic mismatches may lead to direct recog-
nition by donor T-cells, as the T-cell receptor (TCR) contact
residues likely remain similar among allelic mismatches. The poly-
morphisms in allelic mismatches will mostly reside within the
peptide-binding groove, and can thus lead to different peptide
presentation repertoires. Because of the self-HLA restriction of
the TCR, the T cell may still bind to the allelic mismatch and can
then recognize the different peptide repertoire as foreign. With
antigenic mismatches, the self and allogeneic HLA will contain
large numbers of polymorphic residues, and the TCR may not
bind to the mismatched allogeneic HLA anymore. When the TCR
cannot bind to the allogeneic HLA, recognition of the mismatch
will not occur. Therefore, direct recognition seems more likely in
the case of allelic mismatches. In line with this suggestion, previous
in vitro studies have proposed that one should rather mismatch
largely (antigenic) instead of only for a small number of polymor-
phic residues (allelic) (23). The latter study clearly showed that
the chance of the donor developing cytotoxic T-lymphocytic pre-
cursors in vitro was more likely in less polymorphic mismatches,
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Table 2 | HLA-typing of the patient, selected HLA-C mismatch, and potential HLA-B mismatch alternative.
Patient ID Patient HLA-typing Selected HLA-C
mismatch
Potential HLA-B
mismatch
H
LA
-A
H
LA
-B
H
LA
-C
H
LA
-D
R
B
1
H
LA
-D
Q
B
1
H
LA
-C
d
o
n
o
r
P
IR
C
H
E
-I
P
IR
C
H
E
-I
I
H
LA
-B
d
o
n
o
r
P
IR
C
H
E
-I
P
IR
C
H
E
-I
I
1 01:01 02:01 15:01 51:01 03:03 15:02 13:01 15:01 06:02 06:03 07:02 13 16 NA
2 02:01 – 40:01 51:01 03:03 03:04 09:01 13:02 03:03 06:04 05:01 0 1 NI
4 01:01 03:01 08:01 47:01 07:01 03:04 03:01 14:01 02:01 05:03 06:02 4 13 40:01 8 18
10 24:02 24:02 15:01 44:03 03:03 05:01 11:01 12:01 03:01 03:01 04:01 3 24 44:02 2 4
11 02:01 11:01 07:02 18:03 02:02 07:01 11:04 15:01 03:01 06:02 07:02 13 32 NA
14 03:01 32:01 07:02 15:01 07:02 03:03 07:01 13:01 02:02 06:03 01:02 4 15 NA
16 02:01 29:02 44:04 51:01 16:01 15:02 10:01 11:01 05:01 03:01 14:02 14 19 44:03 3 4
23 01:01 02:01 08:01 15:01 03:03 07:01 03:01 04:01 02:01 03:01 03:04 0 1 NI
25 03:01 11:01 07:02 18:01 07:02 12:03 11:01 13:01 03:01 06:03 07:01 9 21 38:01 15 21
29 02:01 – 35:01 51:01 01:02 04:01 13:02 15:01 06:02 06:04 15:02 5 11 27:05 0 7
30 02:01 03:01 13:02 35:01 02:02 04:01 04:01 07:01 02:02 03:02 06:02 6 16 27:05 3 13
31 02:01 11:01 15:01 51:01 04:01 12:03 01:01 04:01 03:02 05:01 03:04 7 13 39:01 12 17
33 02:01 24:02 40:01 57:01 06:02 07:02 07:01 13:02 03:03 06:04 03:04 9 17 07:02 1 16
34 02:01 – 15:01 44:02 03:04 05:01 04:01 04:04 03:01 03:02 03:03 0 0 NI
36 02:01 03:01 07:02 07:02 07:02 02:02 04:04 15:01 03:02 06:02 07:02 7 19 27:05 0 0
40 01:01 02:01 15:01 38:01 04:01 12:03 13:01 13:02 06:03 06:04 12:03 12 14 35:03 0 2
44 11:01 24:02 35:01 35:03 04:01 03:03 04:07 12:01 03:01 – 04:01 3 21 15:01 1 2
46 11:01 68:01 07:02 27:05 02:02 07:02 01:01 07:01 03:03 05:01 01:02 6 20 44:02 2 12
47 01:01 02:01 18:01 27:05 02:02 05:01 11:01 15:01 03:01 06:02 07:01 13 24 44:02 5 13
48 01:01 68:01 44:02 51:01 07:04 14:02 01:01 04:04 03:02 05:01 15:02 3 19 NA
For all our HLA-C mismatched cases, we analyzed the numbers of PIRCHE-I and -II. We next investigated whether we could in theory (based on known haplotypes)
identify an HLA-B mismatch instead of an HLA-C mismatch. In this table, HLA-typing of the patient is displayed, in bold: the actual HLA-C mismatched allele and in
italic: the potential HLA-B mismatched allele. The HLA-typing of the (potential) donors is only displayed for the mismatch, as the other alleles have the same typing.
NA: potential HLA-B mismatched alternative not available; NI: potential HLA-B mismatch not investigated, as the number of HLA-C-derived PIRCHES was low.
suggesting a greater probability of direct recognition by donor
T-cells in vivo. However, as HLA-C cell-surface expression is low,
development of direct recognition is less probable. In line with this
assumption, the previously reported HistoCheck model for direct
recognition of HLA class I mismatches, did not predict alloreactive
complications after HLA-C mismatched HSCT (nor for HLA-A
and -B mismatches) (24). Similarly, the scores obtained with this
direct recognition model showed no correlation to acute GVHD
development in our cohort (p= 0.97). These observations fur-
ther support the hypothesis that indirect recognition may be an
important route of HLA-C mismatches evoking alloreactivity.
HLA-C cell-surface expression is low due to, among other
factors, a limited peptide presentation profile and subsequent
unstable association with β2-microglobulin. This instability leads
to prolonged HLA-C presence in the ER and finally degradation
of the protein. When HLA-C is degraded, it can thereafter be pre-
sented on other HLA proteins as peptides. Indeed, HLA-C-derived
epitopes are frequently diluted from other HLA alleles (16). These
HLA-C-derived PIRCHES can lead to alloreactivity. As HLA-C
allelic mismatches lead to a low number of PIRCHES and antigenic
mismatches to a high number of PIRCHES, indirect recognition
of mismatched HLA-C may explain the risk related to antigenic
HLA-C mismatches and the absence of this relationship for allelic
HLA-C mismatches.
Recently, another study explained the absence of immuno-
genicity of HLA-C allelic mismatches by the predominance of the
HLA-C*03:03/03:04 mismatch combination in this group (25). In
this study, a negative impact on clinical outcomes was observed for
HLA-C antigenic mismatches and any mismatch on HLA-A, -B,
or -DRB1, whereas HLA-C*03:03/03:04 mismatches had similar
outcomes as HLA-A, -B, -C, and -DRB1 matched (8/8) transplan-
tations. In contrast, HLA-C allelic mismatches other than HLA-
C*03:03/03:04 did lead to an increased probability of acute GVHD.
These data may also be explained by the indirect recognition
model, as the HLA-C*03:03/03:04 mismatch leads to a difference
in only one amino acid, and therefore likely yields a low num-
ber of indirectly recognizable epitopes. Indeed, in our cohort, two
patients were transplanted with an HLA-C*03:03/03:04 mismatch,
leading to low PIRCHE-I and -II (Table 2).
HLA-C mismatches can not only lead to T-cell recognition;
B-cell recognition may alternatively lead to alloreactivity upon
HLA-mismatched HSCT. The development of HLA-C specific
www.frontiersin.org May 2014 | Volume 5 | Article 210 | 5
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FIGURE 4 | (A)The number of PIRCHE-I for the selected HLA-C mismatch,
compared to a potential HLA-B mismatch. (B)The number of PIRCHE-II for
the selected HLA-C mismatch, compared to a potential HLA-B mismatch.
For 17 patients with high numbers of mismatched HLA-C-derived PIRCHE-I
and -II, we analyzed whether we could potentially find a mismatched HLA-B
alternative donor. We found that in 7 (54%) of these cases, we could
reduce the number of PIRCHE-I with this strategy and in 9 (69%) of these
cases we could reduce the number of PIRCHE-II. The numbers of PIRCHE-II
are significantly lower when we would have chosen the potential HLA-B
mismatch instead of the selected HLA-C mismatch (Wilcoxon
matched-pairs signed ranked test, p=0.03).
antibodies is correlated to complications after HLA-mismatched
organ transplantation (26). HLAMatchmaker is a well-validated
in silico tool for analyzing such HLA-specific antibody responses
(27, 28). The number of eplets defined by HLAMatchmaker is
correlated to the antibody reactivity against mismatched HLA
(29). Although HLA antibodies may play a role in HSCT out-
come, the HLAMatchmaker algorithm is not suitable to predict
GVH-directed alloreactivity in HLA-mismatched HSCT (30). Par-
ticularly for HLA-C, a correlation between GVHD and HLA-
Matchmaker scores may be unlikely; low cell-surface expression
of HLA-C also limits the potential of binding by HLA-C spe-
cific antibodies to the mismatched alleles. Indeed, in our small
cohort of HLA-C mismatches, HLAMatchmaker scores are also
not correlated to acute GVHD development (p= 0.77).
HLA-C mismatched donors are more frequently selected than
HLA-B mismatched donors, due to the previously mentioned
donor-selection procedures. We have proposed that HLA-B mis-
matches may in some situations lead to a lower probability of
indirect recognition than HLA-C mismatches, and that there-
fore an HLA-B mismatch may be preferred. Although some
studies indicate a particularly strong effect of HLA-B mis-
matched transplantations on detrimental outcomes (13); literature
remains inconclusive regarding a higher risk of HLA-B mismatches
compared to other mismatched loci (9, 11, 12). Before imple-
menting the proposed strategy of selecting donors with the lowest
numbers of PIRCHES, regardless of the locus that is mismatched,
the effect of PIRCHES per mismatched locus should be studied in
a large cohort. Such studies would also allow investigations on the
risk of alloreactivity due to direct recognition in cases with zero
PIRCHES, reflecting the absence of indirect recognition.
To summarize, in this “Hypothesis & Theory” paper, we inves-
tigated whether indirect recognition of HLA-C mismatches may
explain the risk of alloreactivity in the context of the relatively low
cell-surface expression level of HLA-C. We observed a high num-
ber of HLA-C-derived PIRCHES in the case of antigenic HLA-C
mismatches. These high numbers of PIRCHES seem to be cor-
related to an increased acute GVHD risk. We next investigated
whether selection of an HLA-B mismatched donor might lead to
lower numbers of indirectly recognizable epitopes compared to the
selected HLA-C mismatch. Indeed, for a number of patients, we
could identify a potential lower immunogenic alternative. It might
thus be preferable to select a mismatch that leads to the lowest
number of PIRCHES, instead of avoiding mismatches on a spe-
cific locus, although this requires confirmation. This strategy may
reduce the risk of alloreactive complications. We further propose
that future studies investigating the effect of HLA-C, and other
mismatches, on alloreactivity after HSCT with different stem-cell
sources, need to be conducted in large cohorts in order to verify
the clinical relevance of our hypothesis.
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